Sana Biotechnology SANA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's additional paid-in capital?
- Sana Biotechnology (SANA) reported additional paid-in capital of $2.02B in Q1 2026.
- How has Sana Biotechnology's additional paid-in capital changed year-over-year?
- Sana Biotechnology's additional paid-in capital increased by 8.2% year-over-year, from $1.86B to $2.02B.
- What is the long-term trend for Sana Biotechnology's additional paid-in capital?
- Over 5 years (2020 to 2025), Sana Biotechnology's additional paid-in capital has grown at a 200.4% compound annual growth rate (CAGR), from $8.22M to $2.01B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.